NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea · Delayed Price · Currency is KRW 1,768.00
-124.00 (-6.55%)
Oct 12, 2026, 3:30 PM KST
NeoImmuneTech Revenue
NeoImmuneTech had revenue of 1.17B KRW in the quarter ending June 30, 2026, with 4,559.27% growth. This brings the company's revenue in the last twelve months to 1.76B, up 744.13% year-over-year. In the year 2025, NeoImmuneTech had annual revenue of 94.82M, down -44.35%. That makes NeoImmuneTech the 43,142nd largest company in the world by revenue and 2,579th in South Korea.
Revenue (ttm)
1.76B
Revenue Growth
+744.13%
P/S Ratio
99.32
Revenue / Employee
33.85M
Employees
52
Market Cap
174.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.82M | -75.56M | -44.35% |
| Dec 31, 2024 | 170.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 345.88B |
| GC Cell | 162.00B |
| HLB Therapeutics | 64.45B |
| GC Genome | 32.64B |
| SillaJen | 10.77B |
| Anterogen.Co.,Ltd. | 8.37B |
| Genexine | 5.81B |
| MedPacto | 4.99B |